Bad news trumps good for MA, AstraZeneca

In a good news/bad news scenario, Massachusetts is getting the bad news first: AstraZeneca will be cutting 113 jobs at its manufacturing plant in Westborough, about 30 miles west of Boston. Cuts begin in October as the big pharma fights generics-maker Apotex, which is producing a knockoff of AZ's Pulmicort Respules asthma drug, says the Boston Globe.

The good news for the Bay State: AstraZeneca expects to open its expanded research facilities in Waltham, a Boston suburb, in November. The expansion brings the facility to 514,000 square feet from its former 380,000.

And some bad news for AZ (and MedImmune, GlaxoSmithKline and Novartis): swine-flu vaccine developer Serum Institute of India says it is "likely" to sell its vaccine for "one-fifth to one-tenth the cost of similar vaccines being made in Western economies," says a Wall Street Journal report.

- here's the Boston Globe article
- read the Wall Street Journal item

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)